{"query":"Entos Pharmaceuticals John Lewis Fusogenix PLV news","follow_up_questions":null,"answer":null,"images":[],"results":[{"url":"https://www.biotech.ca/news/entos-pharmaceuticals-announces-198-5-million-partnership-with-the-governments-of-canada-and-alberta-to-accelerate-biomanufacturing-of-fusogenix-plv-next-generation-therapeutics/","title":"Entos Pharmaceuticals Announces $198.5 Million ...","content":"The biomanufacturing facility will develop and produce the Entos Fusogenix PLV drug delivery platform and the next generation of medicines.","score":0.9999374,"raw_content":null},{"url":"https://entospharma.com/news-%26-media/f/entos-circio-collaborate-on-in-vivo-plv-circvec-delivery","title":"Entos & Circio collaborate on in vivo PLV-circVec delivery","content":"**Oslo, Norway, Edmonton, Canada and London, United Kingdom, 3 April 2025 –** **Circio Holding ASA (OSE: CRNA),** **a biotechnology company developing powerful circular RNA technology for next generation nucleic acid medicine, and Entos Pharmaceuticals U.K. Ltd. The collaboration will involve joint development and *in vivo* delivery testing of Circio’s optimized circular RNA expression vectors (circVec) using the Entos proprietary Fusogenix™ PLV™ nucleic acid delivery technology. *“Entos is currently partnering with a number of key international genetic medicine companies for the expansion of the use of our* *Fusogenix PLV* *drug delivery system to enable the delivery of nucleic acid to target cells through direct fusion,”* **said Jason Ding, CBO of Entos Pharmaceuticals.***“We have selected to partner with Circio given their unique and impressive approach to circular RNA vector expression technologies for next generation nucleic acid medicine. Circio Holding ASA is a biotechnology company developing powerful circular RNA vector expression technology for next generation nucleic acid medicine.","score":0.99990904,"raw_content":null},{"url":"https://dmdwarrior.com/entos-pharmaceuticals-develops-re-dosable-full-length-dystrophin-gene-therapy-fusogenix-plv-method/","title":"Fusogenix PLV Method - DMD Warrior","content":"Entos Pharmaceuticals Fusogenix PLV platform is a delivery system that combines the best aspects of viral and non-viral approaches.","score":0.999884,"raw_content":null},{"url":"https://finance.yahoo.com/news/chromatin-bioscience-mediphage-bioceuticals-entos-130000563.html","title":"Chromatin Bioscience, Mediphage Bioceuticals, and Entos ...","content":"... Fusogenix PLV platform in projects aimed to improve treatments for rare genetic disorders,\" said John Lewis, CEO of Entos Pharmaceuticals.","score":0.9997981,"raw_content":null},{"url":"https://cureduchenne.org/research/cureduchenne-ventures-invests-in-entos-pharmaceuticals-for-development-of-a-redosable-full-length-dystrophin-gene-therapy/","title":"CureDuchenne Ventures Invests in Entos Pharmaceuticals for ...","content":"“The Fusogenix PLV platform enables the safe, effective, and redosable delivery of full-length functional genes, like dystrophin, to muscle","score":0.9996971,"raw_content":null}],"response_time":0.96,"request_id":"4ab25eab-b087-4e40-9f6a-58403325d5af"}